Related Experiment Video
Updated: Aug 18, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
[Non-small-cell lung cancer third-line therapy with gefitinib]
J R Fischer1, U Haffner, G M Dietrich
1Klinik für Innere Medizin II Onkologie, Klinik Löwenstein, Löwenstein. jr.fischer@klinik-loewenstein.de
Abstract:
The EGFR-inhibition via tyrosine-kinase-inhibitor gefitinib (Iressa) constitutes a new way to treat non-small-cell lung cancer. Recent research results enable us to better understand the basics of molecular targeted therapy (MTT). These results are helpful to re-interpret the clinical results obtained so far for gefitinib and to consider for the first time in a predictive manner factors for the selection of patients suitable for therapy. Three case reports are presented in this paper which illustrate that -- with view to the results from translational research -- the use of gefitinib offers an efficient new therapeutic modality for the treatment of chemotherapy-resistant non-small-cell lung cancer.
Insights
Gefitinib, a tyrosine-kinase-inhibitor targeting EGFR, offers a new treatment for non-small-cell lung cancer. Translational research aids patient selection for this molecular targeted therapy, showing efficacy in chemotherapy-resistant cases.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) treatment landscape.
- Emergence of molecular targeted therapy (MTT).
- Role of Epidermal Growth Factor Receptor (EGFR) in cancer.
Observation:
- Gefitinib (Iressa) is a tyrosine-kinase-inhibitor targeting EGFR.
- Translational research provides insights into MTT.
- Clinical results for gefitinib require re-interpretation.
Findings:
- Gefitinib demonstrates efficacy in chemotherapy-resistant NSCLC.
- Translational research facilitates predictive patient selection for gefitinib therapy.
- Case reports illustrate gefitinib's potential as an efficient therapeutic modality.
Implications:
- Gefitinib represents a novel treatment strategy for NSCLC.
- Understanding MTT basics enhances gefitinib's clinical application.
- Personalized medicine approaches are crucial for optimizing cancer treatment outcomes.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
